Title: Over-the-counter Analgesics in Pregnancy and Offspring Neonatal Outcomes:

A Retrospective Cohort Study

Authors: [1]Aikaterini ZAFEIRI, MSci, Ms, [2]Edwin A. RAJA, PhD, [3]Rod T. MITCHELL,

MBChB, PhD, [4]David C. HAY, PhD, [5]Sohinee BHATTACHARYA, MBBS, PhD, [1]Paul

A. FOWLER, FRSB, PhD

[1]Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition,

University of Aberdeen, Aberdeen, United Kingdom, [2]Medical Statistics Team,

Institute of Applied Health Sciences, School of Medicine, Medical Sciences and

Nutrition, University of Aberdeen, Aberdeen, United Kingdom, [3]MRC Centre for

Reproductive Health, The Queen's Medical Research Institute, University of

Edinburgh,47 Little France Crescent, Edinburgh, EH16 4JT, UK, [4]MRC Centre for

Regenerative Medicine, 5 Little France Drive, Edinburgh, UK, [5]Aberdeen Centre for

Women's Health Research, Institute of Applied Health Sciences, School of Medicine,

Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom,

Corresponding Author: Aikaterini Zafeiri, Institute of Medical Sciences, School of

Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United

Kingdom, cell phone number: (+44)7713837285, email: r01az17@abdn.ac.uk

Running Title: Maternal over-the-counter analgesia and offspring outcomes

Abstract

Objective To identify associations between *in utero* exposure to 5 over-the-counter

(OTC) analgesics and adverse neonatal outcomes.

Design Retrospective cohort study

Setting Aberdeen UK

Population 151,141 singleton deliveries, 1985 to 2015

Methods Self-reported, non-prescription, consumption of paracetamol, aspirin,

ibuprofen, diclofenac and naproxen during pregnancy and neonatal outcomes were

obtained from the Aberdeen Maternity and Neonatal Databank (AMND). Univariable

and multivariable regression analyses were performed to investigate associations

between analgesic use and offspring neonatal outcomes. Crude (cORs) and

adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were reported,

indicating the strength of association.

Main Outcome Measures Premature delivery (<37 weeks), stillbirth, neonatal death,

birthweight, standardised birthweight score, neonatal unit admission, APGAR score

at 1 and 5 minutes, cryptorchidism, neural tube and amniotic band defects,

hypospadias and gastroschisis.

Results Pregnancies exposed to at least one of the 5 analgesics were significantly

independently associated with increased odds for premature delivery <37 weeks

(aOR=1.50, 95%CI 1.43-1.58), stillbirth (aOR=1.33, 95%CI 1.15-1.54), neonatal

death (aOR=1.56, 95%CI 1.27-1.93), birthweight <2500g (aOR=1.28, 95%CI 1.20-

1.37), birthweight >4000g (aOR=1.09, 95%CI 1.05-1.13), admission to neonatal unit

(aOR=1.57, 95%CI 1.51-1.64), APGAR score <7 at 1 minute (aOR=1.18, 95%CI

1.13-1.23) and 5 minutes (aOR=1.48, 95%CI 1.35-1.62), neural tube defects

(aOR=1.64, 95%CI 1.08-2.47) and hypospadias (aOR=1.27, 95%CI 1.05-1.54 males

only).

Conclusions There was a high prevalence of OTC analgesics use during

pregnancy, which steeply increased during the 30-year study period. Analgesic

consumption was independently associated with multiple adverse neonatal offspring

outcomes. The use of paracetamol in combination with other NSAIDs conferred the

highest risk.

Funding Biotechnology and Biological Sciences Research council (BBSRC) funding

under the EASTBIO doctoral training programme.

Key words acetaminophen, aspirin, diclofenac, ibuprofen, *in utero* exposure,

naproxen, offspring outcomes, over-the-counter analgesics, offspring outcomes,

paracetamol, pregnancy

Introduction

Globally 23-85% of women use one or more types of prescribed medications during pregnancy [1,2]. However, an equally high proportion of expectant mothers self-medicate using non-prescription medicines [3,4]. Studies assessing the prevalence of non-prescription analgesic use during pregnancy report an increase, especially in Western countries [5]. However, due to their abundance, it is not always feasible to determine exact consumption rates and dosage. Furthermore, the mechanisms of action for most of these compounds is not fully understood even though most OTC analgesics can diffuse through the placenta and reach the developing fetus [6]. Combined with the altered maternal pharmacokinetics during pregnancy, and the limited pregnancy safety data for these compounds, significant health concerns regarding human exposure and safe use during pregnancy are raised [7].

Some analgesics are considered safe to consume during pregnancy, while use of non-steroidal anti-inflammatory drugs (NSAIDs) is discouraged beyond gestational week 30. Current evidence is conflicting regarding their safety, raising important public health concerns. Several studies have reported increased risks for multiple adverse outcomes including hypospadias, cryptorchidism, amniotic band defects and neural tube defects [8–12], whilst others have not found significant associations [13–18]. However, the use of small cohorts makes it difficult to draw firm conclusions and definite recommendations [13,18–20]. With several study design, methodology and/or result generalisability limitations, more data in larger populations globally are needed to make more informed decisions, which will impact on current practice. Here we report on the prevalence of maternal consumption of five different OTC analgesics during pregnancy and their associations with offspring neonatal outcomes using a

large cohort of pregnancies spanning three decades of data from a single maternity

hospital serving a whole population in the North East of Scotland.

Materials and Methods

This retrospective cohort study utilised data collected in the Aberdeen Maternity and

Neonatal Databank (AMND) in Aberdeen, UK on 151,141 pregnancies over a 30

year period (1985-2015). Details about AMND have been previously published [21].

Data were collected continuously from medical notes of women from their first

antenatal visit and every visit after that. Data were then entered by dedicated coding

staff into a computerised database. Data validity was ensured via checking

completeness of data entry against NHS (UK National Health Service) returns

monthly and constant data cleaning and validation against case notes reported

quarterly by the Data Management team to the AMND Steering Committee. A

research protocol was submitted and approved by the AMND Steering Committee

before data extraction. Approval was received on 6 June 2018. The dataset was fully

anonymised, therefore there was no requirement for NHS ethics committee approval.

The main analysis considered consumption during pregnancy of at least one out of

five different analgesics: paracetamol (no; yes), ibuprofen (no; yes), naproxen (no;

yes), diclofenac (no; yes) or aspirin (no; yes) as the exposure group against no

analgesic consumption as the unexposed group. Then, three sub-group analyses

against the control group were performed using only paracetamol, only diclofenac, or

at least one analgesic from aspirin/naproxen/ibuprofen as exposure groups,

excluding pregnancies exposed to multiple analgesics at the same time. As 98.3% of

pregnancies using diclofenac were between 2005 and 2015, diclofenac sub-group

analysis only considered pregnancies during that time frame in order to rule out any

temporal effect. Analgesic consumption data were available for all pregnancy

trimesters, however exact timing was not specified in the database.

The offspring outcomes compared between control and exposed groups were:

gestation at delivery (preterm <37 gestation weeks, term ≥37 gestation weeks),

pregnancy outcome (livebirth, stillbirth, neonatal death), baby weight (low birth

weight (LBW) ≤2,499g, high birth weight (HBW) ≥4,000g, normal birth weight (NBW)

2,500g-3,999g), standardised birthweight score was considered as a continuous

variable as previously described by Campbell and colleagues (Campbell *et al.*,

1993), baby admission to neonatal unit (no; yes), APGAR score at one and five

minutes (<7, ≥7), cryptorchidism (no; yes) (ICD-10 code Q53), neural tube defects

(no; yes) (ICD-10 code Q00-07), amniotic band defects (no; yes) (ICD-10 codes

Q70-74), hypospadias (no; yes) (ICD-10 code Q54), gastroschisis (no; yes) (ICD-10

code Q79.3). A composite outcome (presence of at least one congenital anomaly

(no; yes)) was created using the variables cryptorchidism, neural tube defects,

amniotic band defects, hypospadias and gastroschisis.

The baseline characteristics compared between exposed and unexposed

pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004,

2005-2015), maternal age at delivery (20-25, <20, 26-35, >35 years), previous

pregnancy (no; yes), maternal body mass index (BMI) (normal weight 18.5-24.9

kg/m^2, underweight <18.5 kg/m^2, overweight 25-29.9 kg/m^2, obese <30 kg/m^2),

maternal first antenatal visit (1st, 2nd, 3rd trimester), maternal smoking status (non-

smoker, smoker, ex-smoker), Scottish Index of Multiple Deprivation (SIMD) decile (1-

6, 7-10, decreasing deprivation with increasing score), maternal hypertensive

disorders (no disorder, gestational hypertension, preeclampsia, eclampsia), maternal

antepartum haemorrhage (no haemorrhage, abruption, placental previa), type of

labour (spontaneous, elective caesarean section, induced), type of delivery

(spontaneous vaginal delivery, instrumental, caesarean section), analgesia during

labour (no; yes), baby presentation at delivery (occiput anterior, occiput posterior),

baby sex (female; male).

Statistical Analysis

Baseline characteristics were compared between exposed and unexposed

pregnancies to any analgesic using χ^2 test for categorical variables and t-test for

normally distributed continuous variables as appropriate. Relationships between

exposures and outcomes were examined by binary logistic regression for binary

outcome variables, multinomial logistic regression for nominal categorical outcome

variables, and multiple linear regression for continuous variables. The strength of

association was reported as odds ratios (ORs) with 95% confidence intervals (CI).

The socio-demographic characteristics that were likely to confound our exposure-to-

outcome path were identified using a directed acyclic graph (DAG) (Figure S1)[23].

Factors that were associated with consumption of OTC analgesics during pregnancy

at 10% level of significance and deemed clinically relevant, were included in the

model as confounders. All outcomes were adjusted for year of delivery, maternal age

at delivery, SIMD and maternal first antenatal visit. In addition to these confounders,

individual outcomes were adjusted for relevant cofactors. Gestation at delivery and

pregnancy outcome were both additionally adjusted for maternal hypertensive

disorders and antepartum haemorrhage. Weight of the baby, neonatal unit

admission, cryptorchidism, neural tube defects, amniotic band defects, hypospadias

and gastroschisis variables were also adjusted for gestation at delivery. APGAR

score at one and five minutes were adjusted for type of delivery. A p-value of less

than 0.05 was considered statistically significant. All statistical analyses were carried

out using IBM SPSS Statistics version 25.0 (Released 2017. IBM SPSS Statistics for

Windows, Armonk, NY: IBM Corp.). R version 3.6.2 was used to generate Figure 2.

Results

Overall, from the total 151,141 pregnancies across 30 years, no OTC analgesic consumption was reported in 107,143 (70.9%) pregnancies. At least one OTC analgesic was consumed in 43,998 (29.1%) pregnancies, whereas paracetamol use alone was reported in 24,099 (18.4%) pregnancies. Diclofenac use was observed in 10,473 (8.9%) pregnancies and at least one out of three analgesics (naproxen, ibuprofen, aspirin) was consumed in 762 (0.7%) pregnancies (Figure 1).

Prevalence of use for all five analgesics increased dramatically over the 30-year study period (1985-2015) (Figure 2). Percentage of pregnancies with consumption of at least one analgesic increased from 1.8% in 1985 to 70.6% in 2015. Paracetamol was consumed in 1.3% of pregnancies in 1985 and it continuously increased reaching 42.2% in 2015. Naproxen, ibuprofen or aspirin consumption during pregnancy was less prevalent (Figure 2A), however it also increased during the 30-year study period, starting at 0.5% in 1985 and reaching 1.9% in 2015 (Figure 2B). Diclofenac was consumed in very few pregnancies between 1985 (<0.01%) and 2005 (0.2%). Percentage of consumption, however, dramatically increased during the next decade, reaching 25.0% in just a year (2006) and 45.6% of all pregnancies in 2015.

Table 1 compares the baseline characteristics between the unexposed group of pregnancies where no analgesic was consumed and each of the exposure groups. In most, but not all, comparisons across all four analyses, there was a statistically significant difference (p<0.001) for most variables. In the paracetamol sub-group analysis, baby presentation at delivery (p=0.525) and sex of the baby (p=0.861) were not significantly different between the groups. In the analysis considering

consumption of at least one analgesic from aspirin/naproxen/ibuprofen, again the

variables for baby presentation at delivery (p=0.093) and sex of the baby (p=0.732),

together with maternal smoking status (p=0.132) and maternal antepartum

haemorrhage (p=0.434) were not statistically different compared to the unexposed

group. All variables were statistically different between unexposed and exposed

groups for the main analysis and diclofenac sub-group analysis.

Table 2 summarises the comparison of neonatal outcomes between the unexposed

group (no analgesic at all) and the exposed groups of at least one analgesic, only

paracetamol and at least one out of aspirin/naproxen/ibuprofen. Comparison of

outcomes for the diclofenac sub-group analysis is shown in Table 3.

All analgesics and neonatal outcomes

As shown in Table 2, compared to unexposed pregnancies in which women did not

use any analgesic, pregnancies with consumption of at least one analgesic

(paracetamol, diclofenac, aspirin, naproxen, ibuprofen) were independently

associated with significantly higher odds for premature delivery (aOR=1.50, 95%CI

1.43-1.58), stillbirth (aOR=1.33, 95%CI1.15-1.54), LBW (aOR=1.28, 95%CI 1.20-

1.37), HBW (aOR=1.09, 95%CI 1.05-1.13), baby admission to neonatal unit

(aOR=1.57, 95%CI 1.51-1.64), APGAR score <7 at five minutes (aOR=1.48, 95%CI

1.35-1.62), neural tube defects (aOR=1.64, 95%CI 1.08-2.47) and hypospadias

(aOR=1.27, 95%CI 1.05-1.54) in adjusted analyses. Significantly decreased odds for

APGAR score <7 at one minute were found in the crude analysis (cOR=0.96, 95%CI

0.92-0.99), however when adjusted for year of delivery, maternal age at delivery,

SIMD, first gestational booking and type of delivery, the significance changed

direction showing significantly increased odds (aOR=1.18, 95%CI 1.13-1.23). A

significantly lower standardised birthweight score (aOR=0.046. 95%CI 0.032-0.059)

was found for the exposure group compared to no analgesic at all. Cryptorchidism

(aOR=0.92, 95%CI 0.77-1.11), amniotic band defects (aOR=1.02, 95%CI 0.71-1.47),

gastroschisis (aOR=1.10, 95%CI 0.56-2.20) and the composite outcome variable

(aOR=1.12, 95%CI 0.99-1.26), were all associated with increased odds in the

exposure group compared to not exposed, however the association was not

significant in the adjusted model. There was no significant association between

neonatal death and exposure to at least one analgesic in the crude analysis

(cOR=1.19, 95%CI 0.99-1.42), however there were significantly higher odds of

neonatal death in the adjusted analysis (aOR=1.56, 95%CI 1.27-1.93) in the

exposed group compared to control.

218   Paracetamol and neonatal outcomes

In the sub-group analysis considering only paracetamol consumption during

pregnancy as our exposure group, most of the associations reported in the main

analysis remained significant with the same direction of significance (Table 2). The

differences were: maternal paracetamol consumption during pregnancy was

associated with significantly decreased odds for offspring HBW (cOR=0.94, 95%CI

0.90-0.99) in the crude analysis however significance was lost in the adjusted model

(aOR=0.98, 95%CI 0.93-1.02), and there were no significant associations in the

adjusted models for neural tube defects (aOR=1.21, 95%CI 0.71-2.06) and

hypospadias (aOR=1.07, 95%CI 0.84-1.37).

229   Aspirin/naproxen/ibuprofen and neonatal outcomes

Consumption of at least one analgesic from aspirin, naproxen or ibuprofen during

pregnancy was compared against the same control group of pregnancies where no

analgesic was used (Table 2). Again, when comparing associations between groups

in this sub-group analysis and main analysis, fewer outcome variants showed similar

significance pattern. The only shared significant associations were for increased

odds for premature delivery (aOR=1.42, 95%CI 1.08-1.86), stillbirth (aOR=2.34,

95%CI 1.29-4.25) and baby admission to neonatal unit (aOR=1.54, 95%CI 1.22-

1.94) in the adjusted regression analyses.

239 Diclofenac and neonatal outcomes

In the sub-group analysis of pregnancies only exposed to diclofenac, years 2005-

2015 were considered, and outcomes were again compared between the diclofenac

group and no analgesic consumption group (Table 3). Compared to the main

analysis, diclofenac consumption during pregnancy was not significantly associated

with premature delivery (aOR=1.10, 95%CI 0.99-1.22), neonatal death (aOR=1.26,

95%CI 0.73-2.15) and APGAR score <7 in one minute (aOR=0.93, 95%CI 0.83-1.04)

in the adjusted models. Associations with APGAR score <7 in five minutes

(aOR=0.94, 95%CI 0.72-1.23), cryptorchidism (aOR=1.05, 95%CI 0.78-1.42),

amniotic band defects (aOR=0.81, 95%CI 0.41-1.58) and gastroschisis (aOR=2.93,

95%CI 0.97-8.88) were no longer significant in both crude and adjusted analyses.

Maternal consumption of diclofenac was independently associated with a significant

decrease in stillbirth (aOR=0.59, 95%CI 0.41-0.87). It is also interesting to note that

diclofenac was the only sub-group analysis agreeing with the main analysis

(exposure to at least one analgesic) on the significance of exposure association with

increased incidence of neural tube defects (aOR=3.62, 95%CI 1.95-6.74) and

hypospadias (aOR=1.49, 95%CI 1.09-2.03) compared to unexposed pregnancies in

adjusted models.

Discussion

Main Findings

There was a dramatic increase in the frequency of OTC (non-prescription) analgesic

use in pregnancies between 1985 and 2015. Diclofenac use increased steeply from

2005 (Figure 2A), which reflects the change in Scottish legislation making diclofenac

available without prescription in that year. Consumption of paracetamol, ibuprofen,

aspirin and naproxen during pregnancy, either in combination or separately, was

significantly associated with increased premature delivery, stillbirth, neonatal death,

LBW, abnormal standardised birthweight score and more frequent admission to

neonatal unit. Consumption of paracetamol alone was further associated with higher

odds for APGAR score <7 at one and five minutes both in crude and adjusted

analyses.

Surprisingly, exposure to diclofenac only was associated with significant decrease of

stillbirth incidence both in crude and adjusted models. Another striking difference of

diclofenac with the rest of the analyses was its association with a significant increase

of neural tube defects and hypospadias. The reason for such deviation of diclofenac

results with the other analgesics might be an underlying maternal condition and/or

other compounds used in combination (e.g. prescriptions) by women taking

diclofenac. It is possible that the drug could act directly on fetal development then

this difference could also be due to structural and/or mechanistic differences of the

compound compared to the other drugs, but further studies are required to assess

this. Overall, comparing our main analysis with all three sub-analyses, it is evident

that the most significant differences were observed when paracetamol was taken

with at least one other analgesic. This is mostly due to the high number of

pregnancies where paracetamol was used, comprising almost 55% of the exposed

cases in the main analysis.

Strengths and Limitations

A major strength of the present study is the large cohort of 151,141 pregnancies over

a 30-year study period from 1985 until 2015, using a robust data source AMND. The

dataset contains high quality and consistent data from the geographically defined

area of Aberdeen and surrounding district, in the North East of Scotland, UK. In

addition, as Aberdeen Maternity Hospital is the only maternity hospital serving the

area, over 95% of pregnancies in the area are included in the dataset, minimizing the

risk for selection bias. We were able to analyse maternal consumption data of the

five most commonly used analgesics available OTC in the UK and most countries.

The nature of our data allowed for the analysis of analgesics consumed alone or in

combination, better reflecting real-life consumption patterns [43,44]. We were able to

adjust for important confounding factors, relevant to each analysed outcome.

Adjustment for maternal deprivation also allowed us to further account for potential

unmeasured factors that can influence maternal and neonatal health, which is a

major strength of our analysis compared to most studies.

A potential concern was that women were probably using analgesics to treat some

inherent medical condition which in turn could have been the mediating factor for

adverse outcomes. However, since these medications are widely available without

prescription, this is unlikely to be a factor that affects the findings of this study.

This study presents results on multiple neonatal outcomes for the given cohort,

offering a comprehensive approach to the exploration of associations with *in utero*

analgesic exposure than only focusing on a single outcome of interest. Our data

were based on medical notes; however OTC consumption is self-reported, and

details on the timing, dosage, product type (single-ingredient vs combination) and

administration type were not available in the database. Complete case analyses

were performed ignoring pregnancies with missing data in the covariates, however

due to the low number of missing data there is little chance that this might have

affected the validity of our results. Compared to our cohort size, there were overall

very few cases of cryptorchidism, neural tube defects, amniotic band defects,

hypospadias and gastroschisis, resulting in potentially underpowered statistical

analyses to detect a difference for these outcomes. Our study only considered

neonatal health outcomes and follow-up of the offspring was not available at this

time.

Interpretation

Previous literature has considered fewer outcomes with fewer analgesic

combinations compared to our study. Consistent with our results, increased risk of

preterm birth and miscarriage has been associated with analgesic consumption

during pregnancy [24–27], while others reported no associations with miscarriage,

stillbirth or preterm delivery [20,24,25,28]. Similarly, increased risk for offspring

cryptorchidism, hypospadias, neural tube defects, amniotic band defects and

gastroschisis have been shown by many studies [8,9,36,10,29–35], although, again, a lack

of associations with major birth defects have been reported [14–18,37,38]. Compared to

our analysis, all these studies used a smaller cohort, considered a shorter study time

and there was frequent disagreement with respect to the choices of adjusted

confounding factors. Another difference is that maternal questionnaires/interviews

were frequently the method of choice to evaluate maternal consumption. Some of

the studies reported increased risks for specific pregnancy trimesters which is

something our study could not evaluate. Differences in study design and adjustment

for different confounders might also account for the disagreement of our results that

provide a more accurate assessment. Our study is one of the largest in terms of

cohort size, duration, number of analgesics and range of outcomes included which

might also contribute to differences compared to other studies.

The literature currently reports conflicting evidence, limiting our ability for definite

decision-making. OTC analgesics are recommended to women by healthcare

professionals in order to deal with pregnancy symptoms and other conditions. Policy-

makers have taken a stand on the topic, either being reassuring about OTC use

during pregnancy or recommending caution when consumption is necessary [39–42].

Different compounds can affect the mother and the fetus in a different way, and their

combined use might worsen the risk for offspring ill health. This study demonstrates

the need for additional research, before the field can be confidently directed towards

one direction or the other.

Whether the associations we report result from flu, fever, rheumatological or

inflammatory conditions, and/or combination with other prescribed medications or

solely related to OTC analgesics consumption is a matter of further research.

Underlying health conditions could well influence the outcomes we see in this study,

however, as these could be very different conditions it is biologically unlikely that

they are responsible for the effects we observe here. Our study demonstrates an

association of maternal OTC analgesic consumption during pregnancy with adverse

neonatal offspring outcomes. Future collaborative approaches such as an individual

patient data meta-analysis that includes follow-up data on long-term outcomes

during childhood and adulthood would significantly inform decision making. Going

forward, uncovering the mechanisms of action and off target effects will also provide

a solid foundation for the development of pregnancy-safe compounds.

Conclusions

Pain control is currently a therapeutic priority during pregnancy. Our results highlight

that data on adverse health outcomes for the offspring are crucial to inform

guidelines and policies for the management of pain during pregnancy using OTC

analgesics that are available without prescription, which is safe for both the mother

and the fetus.

Acknowledgements: N/A

Disclosure of interests: Professor David Hay is a founder, director and shareholder

in Stemnovate Limited. The remaining authors have no interests to disclose.

Contribution to Authorship: AZ, SB and PAF contributed to the conception, design

and coordination of the research. EAR provided critical input in the design and

planning of statistical analysis. AZ conducted the statistical analysis and prepared

the manuscript, figures and tables. AZ, SB, PAF, RTM and DCH substantially

contributed to the analysis and interpretation of the work. All authors contributed to

critical discussion of intellectual content, development and review/approval of the

final manuscript version.

Funding: This work is supported by the Biotechnology and Biological Sciences

Research council (BBSRC) funding the lead author under the EASTBIO doctoral

training programme. RTM is supported by UKRI Future Leaders Fellowship

(MR/S017151/1). The MRC Centre for Reproductive Health is supported by MRC

Centre Grant (MR/N022556/1). The funders had no role in study design, data

collection, data analysis, decision to publish, or manuscript preparation.

Ethics Statement: The AMND dataset used in this study was fully anonymised,

therefore there was no requirement for ethical approval. The North of Scotland

Research Ethics Service has devolved Caldicott approval to the Chair of the AMND

steering committee. Approval to access and analyse data was obtained from the

AMND steering Committee (AMND 004/2018).

References

1.   Gendron M-P, Martin B, Oraichi D, Berard A. Health care providers' requests to Teratogen Information Services on medication use during pregnancy and lactation. *Eur J Clin Pharmacol.* 2009;65(5):523-531.

2.   Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. *Am J Obstet Gynecol.* 2011;205(1):51.e1-51.e8.

3.   Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. *Am J Obstet Gynecol.* 2005;193(3):771-777.

4.   Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. *Am J Obstet Gynecol.* 2003;188(4):1039-1045.

5.   Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: A cross-sectional, multinational web-based study. *BMJ Open.* 2014;4(2).

6.   Nitsche JF, Patil AS, Langman LJ, et al. Transplacental Passage of Acetaminophen in Term Pregnancy. *Am J Perinatol.* 2017;34(6):541-543.

7.   Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. Chappell LC, ed. *PLoS Med.* 2016;13(11):e1002160.

8.   Lynberg MC, Khoury MJ, Lu X, Cocian T. Maternal flu, fever, and the risk of neural tube defects: A population-based case-control study. *Am J Epidemiol.* 1994;140(3):244-255.

9.   Werler MM, Louik C, Mitchell AA. Epidemiologic analysis of maternal factors

and amniotic band defects. *Birth Defects Res Part A - Clin Mol Teratol.*

2003;67(1):68-72.

10.   Snijder CA, Kortenkamp A, Steegers EAP, et al. Intrauterine exposure to mild

analgesics during pregnancy and the occurrence of cryptorchidism and

hypospadia in the offspring: The Generation R Study. *Hum Reprod.*

2012;27(4):1191-1201.

11.   Lind JN, Tinker SC, Broussard CS, et al. Maternal medication and herbal use

and risk for hypospadias: Data from the National Birth Defects Prevention

Study, 1997-2007. *Pharmacoepidemiol Drug Saf.* 2013;22(7):783-793.

12.   Interrante JD, Ailes EC, Lind JN, et al. Risk comparison for prenatal use of

analgesics and selected birth defects, National Birth Defects Prevention Study

1997–2011. *Ann Epidemiol.* 2017;27(10):645-653.e2.

13.   Philippat C, Gorgis-Allemand L, Chevrier C, et al. Analgesics during pregnancy

and undescended testis. *Epidemiology.* 2011;22(5):747-749.

14.   Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. Nonsteroidal

antiinflammatory drug use among women and the risk of birth defects. In:

American Journal of Obstetrics and Gynecology. Vol 206. Mosby Inc.;

2012:228.e1-228.e8.

15.   Cassina M, De Santis M, Cesari E, et al. First trimester diclofenac exposure

and pregnancy outcome. *Reprod Toxicol.* 2010;30(3):401-404.

16.   Padberg S, Tissen-Diabaté T, Dathe K, et al. Safety of diclofenac use during

early pregnancy: A prospective observational cohort study. *Reprod Toxicol.*

2018;77:122-129.

17. van Gelder MMHJ, Roeleveld N, Nordeng H. Exposure to non-steroidal anti-

inflammatory drugs during pregnancy and the risk of selected birth defects: A

prospective cohort study. *PLoS One*. 2011;6(7).

18. Dathe K, Fietz AK, Pritchard LW, et al. No evidence of adverse pregnancy

outcome after exposure to ibuprofen in the first trimester – Evaluation of the

national Embryotox cohort. *Reprod Toxicol*. 2018;79:32-38.

19. McElhatton PR, Sullivan FM, Volans GN. Paracetamol overdose in pregnancy

analysis of the outcomes of 300 cases referred to the teratology information

service. *Reprod Toxicol*. 1997;11(1):85-94.

20. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of

aspirin consumption during pregnancy on pregnancy outcomes: Meta-analysis.

Birth Defects Res Part B - Dev Reprod Toxicol. 2003;68(1):70-84.

21. Ayorinde AA, Wilde K, Lemon J, Campbell D, Bhattacharya S. Data resource

profile: The Aberdeen Maternity and Neonatal Databank (AMND). *Int J

Epidemiol*. 2016;45(2):389-394.

22. Campbell D, Hall M, Lemon J, Carr-Hill R, Pritchard C, Samphier M. Clinical

birthweight standards for a total population in the 1980s. *BJOG An Int J Obstet

Gynaecol*. 1993;100(5):436-445.

23. Textor J, van der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GT. Robust

causal inference using directed acyclic graphs: The R package "dagitty." *Int J

Epidemiol*. 2016;45(6):1887-1894.

24. Rebordosa C, Kogevinas M, Bech BH, Sørensen HT, Olsen J. Use of

acetaminophen during pregnancy and risk of adverse pregnancy outcomes. *Int*
J Epidemiol. 2009;38(3):706-714.

25. Nielsen GL, Sørensen HT, Larsen H, Pedersen L. Risk of adverse birth
outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory
drugs: Population based observational study and case-control study. *Br Med J.*
2001;322(7281):266-270.

26. Czeizel AE, Dudá I, Puhó E. Short-term paracetamol therapy during pregnancy
and a lower rate of preterm birth. *Paediatr Perinat Epidemiol.* 2005;19(2):106-
111.

27. Li Z, Ren A, Liu J, et al. Maternal flu or fever, medication use, and neural tube
defects: A population-based case-control study in northern China. *Birth*
Defects Res Part A - Clin Mol Teratol. 2007;79(4):295-300.

28. Pastore LM, Hertz-Picciotto I, Beaumont JJ. Risk of stillbirth from medications,
illnesses and medical procedures. *Paediatr Perinat Epidemiol.* 1999;13(4):421-
430.

29. Kristensen DM, Hass U, Lesn L, et al. Intrauterine exposure to mild analgesics
is a risk factor for development of male reproductive disorders in human and
rat. *Hum Reprod.* 2011;26(1):235-244.

30. Jensen MS, Rebordosa C, Thulstrup AM, et al. Maternal use of
acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk
of cryptorchidism. *Epidemiology.* 2010;21(6):779-785.

31. Correy JF, Newman NM, Collins JA, Burrows EA, Burrows RF, Curran JT. Use
of prescription drugs in the first trimester and congenital malformations. *Aust N*

Z J Obs Gynaecol. 1991;31(4):340-344.

32.   Lind DV, Main KM, Kyhl HB, et al. Maternal use of mild analgesics during

483   pregnancy associated with reduced anogenital distance in sons: A cohort

484   study of 1027 mother-child pairs. *Hum Reprod.* 2017;32(1):223-231.

485   33.   Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in

486   relation to gastroschisis. *Teratology.* 1992;45(4):361-367.

487   34.   Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJR. Maternal medications

488   and environmental exposures as risk factors for gastroschisis. *Teratology.*

489   1996;54(2):84-92.

490   35.   M. Werler M, Sheehan JE, Mitchell AA. Maternal medication use and risks of

491   gastroschisis and small intestinal atresia. *Am J Epidemiol.* 2002;155(1):26-31.

492   36.   Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin

493   consumption during the first trimester of pregnancy and congenital anomalies:

494   A meta-analysis. *Am J Obstet Gynecol.* 2002;187(6):1623-1630.

495   37.   Slone D, Heinonen OP, Kaufman DW, Siskind V, Monson RR, Shapiro S.

496   ASPIRIN AND CONGENITAL MALFORMATIONS. *Lancet.*

497   1976;307(7974):1373-1375.

498   38.   Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever,

499   and medication use as risk factors for neural tube defects. *Teratology.*

500   1998;57(1):1-7.

501   39.   Mosley II JF, Smith LL, Dezan MD. An overview of upcoming changes in

502   pregnancy and lactation labeling information. *Pharm Pract (Granada).*

503   2015;13(2):605.

40.   SMFM (Society for Maternal-Fetal Medicine Publications Committee). Prenatal

acetaminophen use and outcomes in children. *Am J Obstet Gynecol*.

2017;216(3):B14-B15.

41.   Bisson DL, Newell SD, Laxton C. Antenatal and Postnatal Analgesia: Scientific

Impact Paper No. 59. *BJOG An Int J Obstet Gynaecol*. 2018;(59).

42.   RCOG. RCOG review clarifies pain relief options for women during pregnancy

and breastfeeding. https://www.rcog.org.uk/en/news/new-rcog-review-clarifies-

pain-relief-options-for-women-during-pregnancy-and-breastfeeding/. Published

2018.

43.   Sarganas G, Buttery AK, Zhuang W, et al. Prevalence, trends, patterns and

associations of analgesic use in Germany. *BMC Pharmacol Toxicol*.

2015;16(1).

44.   Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in

France over the last 10 years and comparison of patterns across Europe. *Br J*

Clin Pharmacol. 2018;84(6):1324-1334.

Table 1. Comparison of baseline characteristics between exposed (use of analgesics) and unexposed (no analgesic use) groups of pregnancies (P values <0.05 shown in bold).

Baseline Characteristics	No analgesic (n=107,143) n (%)	At least one analgesic (n=43,998) n (%)	P value†	Paracetamol (n=24,099) n (%)	P value†	Ibuprofen/ Aspirin/ Naproxen (n=762) n (%)	P value†	No analgesic 2005-2015 (n=20,544) n (%)	Diclofenac 2005-2015 (n=10,291) n (%)	P value‡
Year of delivery										
1985-1994	50,152 (46.8)	5,737 (13.0)	**<0.001**	5,390 (22.4)	**<0.001**	213 (28.0)	**<0.001**	n/a	n/a	**<0.001**
1995-2004	36,447 (34.0)	7,263 (16.5)		6,571 (27.3)		321 (42.1)		n/a	n/a	
2005-2015 / 2005-2009 *	20,544 (19.2)	30,998 (70.5)		12,138 (50.4)		228 (29.9)		11,105 (54.1)	4,021 (39.1)	
2010-2015 *	n/a	n/a		n/a		n/a		9,439 (45.9)	6,270 (60.9)	
Maternal age at delivery										
Younger than 20	9,236 (8.6)	3,834 (8.7)	**<0.001**	2,936 (12.2)	**<0.001**	34 (4.5)	**<0.001**	1,286 (6.3)	311 (3.0)	**<0.001**
20-25	24,249 (22.6)	8,700 (19.8)		5,932 (24.6)		113 (14.8)		3,436 (16.7)	1,152 (11.2)	
26-35	63,499 (59.3)	25,367 (57.7)		12,896 (53.5)		464 (60.9)		12,664 (61.1)	6,628 (64.4)	
Older than 35	10,159 (9.5)	6,097 (13.9)		2,335 (9.7)		151 (19.8)		3,158 (15.4)	2,200 (21.4)	
Previous Parity										
Nulliparity (0)	48,684 (45.4)	23,353 (53.1)	**<0.001**	12,510 (51.9)	**<0.001**	300 (39.4)	**0.004**	8,336 (40.6)	5,004 (48.6)	**<0.001**
Multiparity (1-11)	58,457 (54.6)	20,639 (46.9)		11,587 (48.1)		462 (60.6)		12,206 (59.4)	5,284 (51.4)	
Missing	2 (<0.1)§	6 (<0.1)§		2 (<0.1)§		0 (0.0)§		2 (<0.1)§	3 (<0.1)§	
Maternal BMI										
Underweight (<18.5)	1,998 (2.4)	869 (2.2)	**<0.001**	545 (2.6)	**<0.001**	10 (1.5)	**0.007**	492 (2.7)	174 (1.9)	**<0.001**
Normal weight (18.5-24.9)	50,127 (60.8)	18,958 (48.8)		10,486 (50.5)		361 (55.)		10,239 (55.2)	4,671 (50.0)	
Overweight (25.0-29.9)	20,500 (24.9)	10,960 (28.2)		5,733 (27.6)		192 (29.5)		4,930 (26.6)	2,630 (28.1)	
Obese ($\leq$ 30.0)	9,773 (11.9)	8,046 (20.7)		3,995 (19.2)		88 (13.5)		2,881 (15.5)	1,871 (20.0)	
Missing data	24,745 (23.1)§	5,165 (11.7)§		3,340 (13.9)§		111 (14.6)§		2,002 (9.7)§	945 (9.2)§	

Gestation weeks at earliest antenatal visit										
1st Trimester	69,896 (65.4)	36,789 (83.7)	<0.001	19,075 (79.2)	<0.001	569 (75.0)	<0.001	18,155 (88.4)	9,185 (89.4)	**0.036**
2nd Trimester	29,269 (27.4)	5,791 (13.2)		4,117 (17.1)		166 (21.9)		1,770 (8.6)	829 (8.1)	
3rd Trimester	7,741 (7.2)	1,376 (3.1)		890 (3.7)		24 (3.2)		605 (2.9)	264 (2.6)	
Missing	237 (0.2)§	42 (0.1)§		17 (0.1)§		3 (0.4)§		14 (0.1)§	13 (0.1)§	
Maternal smoking Status										
Unknown	6,505 (6.1)§	819 (1.9)§	<0.001	500 (2.1)§	<0.001	32 (4.2)§	0.132	448 (2.2)§	155 (1.5)§	**<0.001**
Ex-smoker	5,952 (5.6)	3,363 (7.6)		1,923 (8.1)		35 (4.8)		1,427 (7.1)	660 (6.5)	
Non-smoker	70,319 (69.9)	31,421 (72.8)		15,755 (66.8)		534 (73.2)		15,525 (77.3)	8,368 (82.6)	
Smoker	24,367 (24.2)	8,395 (19.4)		5,921 (25.1)		161 (22.)		3,144 (15.6)	1,108 (10.9)	
Maternal SIMD Decile										
Least Deprived (7-10)	65,227 (61.8)	25,192 (57.9)	<0.001	12,807 (53.8)	<0.001	501 (66.3)	**0.012**	12,806 (62.9)	6,714 (66.1)	**<0.001**
Most Deprived (1-6)	40,321 (38.2)	18,289 (42.1)		11,017 (46.2)		255 (33.7)		7,564 (37.1)	3,442 (33.9)	
Missing	1,595 (1.5)§	517 (1.2)§		275 (1.1)§		6 (0.8)§		174 (0.8)§	135 (1.3)§	
Maternal hypertensive disorders										
None	91,276 (85.2)	35,529 (80.8)	<0.001	18,635 (77.3)	<0.001	636 (83.5)	**0.001**	18,851 (91.8)	9,273 (90.1)	**<0.001**
Gestational Hypertension	13,029 (12.2)	5,501 (12.5)		3,584 (14.9)		88 (11.5)		1,165 (5.7)	690 (6.7)	
Preeclampsia	2,780 (2.6)	2,941 (6.7)		1,861 (7.7)		38 (5.0)		523 (2.5)	324 (3.1)	
Eclampsia	58 (0.1)	27 (0.1)		19 (0.1)		0 (0.0)		5 (<0.1)	4 (<0.1)	
Maternal antepartum haemorrhage										
No haemorrhage	97,527 (91.0)	37,673 (85.6)	<0.001	20,306 (84.3)	<0.001	684 (89.8)	0.434	18,549 (90.3)	9,244 (89.8)	<0.001
Abruption	697 (0.7)	468 (1.1)		221 (0.9)		8 (1.0)		103 (0.5)	106 (1.0)	
Placenta previa	308 (0.3)	368 (0.8)		152 (0.6)		2 (0.3)		23 (0.1)	114 (1.1)	
Unspecified	8,611 (8.0)	5,489 (12.5)		3,420 (14.2)		68 (8.9)		1,869 (9.1)	827 (8.0)	
Type of labour										
Elective Caesarean Section	5,967 (5.6)	6,925 (15.7)	<0.001	1,384 (5.7)	<0.001	67 (8.8)	<0.001	616 (3.0)	3,843 (37.3)	**<0.001**
Induced	24,120 (22.5)	16,276 (37.0)		10,067 (41.8)		228 (29.9)		3,895 (19.0)	1,998 (19.4)	
Spontaneous	77,056 (71.9)	20,797 (47.3)		12,648 (52.5)		467 (61.3)		16,033 (78.0)	4,450 (43.2)	

Type of delivery										
Spontaneous vaginal delivery (SVD)	75,027 (70.1)	19,287 (43.8)	**<0.001**	15,983 (66.3)	**<0.001**	496 (65.2)	**0.003**	16,398 (79.8)	1,403 (13.6)	**<0.001**
Instrumental	15,409 (14.4)	8,107 (18.4)		4,043 (16.8)		120 (15.8)		2,546 (12.4)	1,927 (18.7)	
Caesarean Section	15,566 (14.5)	16,351 (37.2)		3,879 (16.1)		141 (18.5)		1,509 (7.3)	6,937 (67.4)	
Other	1,096 (1.0)	247 (0.6)		191 (0.8)		4 (0.5)		89 (0.4)	24 (0.2)	
Missing	45 (<0.1)**§**	6 (<0.1)**§**		3 (<0.1)**§**		1 (0.1)**§**		2 (<0.1)**§**	0 (0.0)**§**	
Analgesia during labour										
No	105,176 (98.2)	36,117 (82.1)	**<0.001**	20,974 (87.0)	**<0.001**	729 (95.7)	**<0.001**	19,915 (96.9)	8,235 (80.0)	**<0.001**
Yes	1,967 (1.8)	7,881 (17.9)		3,125 (13.0)		33 (4.3)		629 (3.1)	2,056 (20.0)	
Baby presentation at delivery										
Occiput anterior	11,571 (10.8)	8,152 (18.6)	**<0.001**	2,636 (11.0)	0.525	68 (8.9)	0.093	1,401 (6.8)	2,967 (28.9)	**<0.001**
Occiput posterior	95,352 (89.2)	35,745 (81.4)		21,409 (89.0)		694 (91.1)		19,100 (93.2)	7,306 (71.1)	
Missing	220 (0.2)**§**	101 (0.2)**§**		54 (0.2)**§**		0 (0.0)**§**		43 (0.2)**§**	18 (0.2)**§**	
Sex of baby										
Female	52,265 (48.8)	21,139 (48.0)	**0.010**	11,739 (48.7)	0.861	367 (48.2)	0.732	10,124 (49.3)	4,907 (47.7)	**0.008**
Male	54,866 (51.2)	22,852 (51.9)		12,354 (51.3)		395 (51.8)		10,417 (50.7)	5,384 (52.3)	
Missing	12 (<0.1)**§**	7 (<0.1)**§**		6 (<0.1)**§**		0 (0.0)**§**		3 (<0.1)**§**	0 (0.0)**§**	

520 n/a, not applicable; n, number of pregnancies

521 ***** Only applicable to Diclofenac 2005-2015 analysis

522 **†** p value in comparison to the first ("No analgesic") column

523 **‡** p value in comparison to "No analgesic 2005-2015" control column

524 **§** Percentage of missing data on total, not included in the analysis

Table 2. Regression analysis of offspring outcomes between control (no analgesic) and groups exposed to at least one analgesic, only paracetamol, and at least one from ibuprofen, aspirin, naproxen.

Outcomes	No analgesic (n=107,143) n (%)	At least one analgesic (n=43,998) n (%)	Crude OR (CI 95%)	Adjusted OR (95% CI)	Paracetamol (n=24,099) n (%)	Crude OR (95% CI)	Adjusted OR (95% CI)	Ibu/Asp/Napr (n=762) n (%)	Crude OR (95% CI)	Adjusted OR (95% CI)
Gestation at delivery (weeks)										
>=37	100,879 (94.2)	39,838 (90.5)	1.00	1.00	21,589 (89.6)	1.00	1.00	697 (91.5)	1.00	1.00
<37	6,264 (5.8)	4,160 (9.5)	**1.68 (1.61-1.75)**	**1.50 (1.43-1.58) [a]**	2,510 (10.4)	**1.87 (1.78-1.97)**	**1.56 (1.48-1.65) [a]**	65 (8.5)	**1.50 (1.16-1.94)**	**1.42 (1.08-1.86) [a]**
Pregnancy outcome										
Livebirth	105,949 (98.9)	43,407 (98.7)	1.00	1.00	23,704 (98.4)	1.00	1.00	747 (98.0)	1.00	1.00
Stillbirth	803 (0.7)	405 (0.9)	**1.23 (1.09-1.39)**	**1.33 (1.15-1.54) [a]**	275 (1.1)	**1.53 (1.33-1.76)**	**1.52 (1.30-1.77) [a]**	13 (1.7)	**2.30 (1.32-3.99)**	**2.34 (1.29-4.25) [a]**
Neonatal Death	373 (0.3)	182 (0.4)	1.19 (0.99-1.42)	**1.56 (1.27-1.93) [a]**	117 (0.5)	**1.40 (1.14-1.73)**	**1.56 (1.24-1.96) [a]**	2 (0.3)	0.76 (0.19-3.06)	0.93 (0.23-3.74) [a]
Missing	18 (<0.1)	4 (<0.1)	n/a	n/a	3 (<0.1)	n/a	n/a	0 (0.0)	n/a	n/a
Weight of baby (grams)										
NBW	87,966 (82.1)	34,555 (78.6)	1.00	1.00	19,163 (79.5)	1.00	1.00	605 (79.5)	1.00	1.00
LBW	5,910 (5.5)	3,571 (8.1)	**1.54 (1.47-1.61)**	**1.28 (1.20-1.37) [b]**	2,213 (9.2)	**1.72 (1.63-1.81)**	**1.60 (1.51-1.69) [b]**	59 (7.7)	**1.45 (1.11-1.90)**	1.29 (0.91-1.83) [b]
HBW	13,233 (12.4)	5,863 (13.3)	**1.13 (1.09-1.17)**	**1.09 (1.05-1.13) [b]**	2,720 (11.3)	**0.94 (0.90-0.99)**	0.98 (0.93-1.02) [b]	97 (12.7)	1.07 (0.86-1.32)	0.99 (0.80-1.24) [b]
Missing	34 (<0.1)	9 (<0.1)	n/a	n/a	3 (<0.1)	n/a	n/a	1 (0.1)	n/a	n/a
Standardised Birthweight Score										
Mean (SD)	0.001 (0.003)	-0.002 (0.065)	**0.03 (0.02-0.04)**	**0.046 (0.032-0.059) [c]**	0.001 (0.991)	**-0.04 (-0.058- -0.029)**	**-0.014 (-0.029-0.001) [c]**	0.046 (0.038)	**0.045 (-0.029-0.119)**	**0.049 (-0.025-0.123) [c]**
Admitted to neonatal unit										
No	62,378 (58.2)	32,391 (73.6)	1.00	1.00	16,342 (67.8)	1.00	1.00	480 (63.0)	1.00	1.00
Yes	11,011 (10.3)	7,448 (16.9)	**1.30 (1.26-1.35)**	**1.57 (1.51-1.64) [b]**	3,956 (16.4)	**1.37 (1.32-1.43)**	**1.45 (1.38-1.53) [b]**	117 (15.4)	**1.38 (1.13-1.69)**	**1.54 (1.22-1.94) [b]**
Missing	33,754 (31.5)	4,159 (9.5)	n/a	n/a	3,801 (15.8)	n/a	n/a	762 (21.7)	n/a	n/a
APGAR score at 1 min										
Normal	92,217 (86.1)	38,224 (86.9)	1.00	1.00	20,593 (85.5)	1.00	1.00	659 (86.5)	1.00	1.00
<7	14,335 (13.4)	5,674 (12.9)	**0.96 (0.92-0.99)**	**1.18 (1.13-1.23) [d]**	3,437 (14.3)	**1.07 (1.03-1.12)**	**1.23 (1.18-1.28) [d]**	101 (13.3)	0.99 (0.80-1.22)	1.07 (0.86-1.32) [d]
Missing	591 (0.6)	100 (0.2)		n/a	69 (0.3)	n/a	n/a	2 (0.3)	n/a	n/a
APGAR score at 5 min										
Normal	104,292 (97.3)	42,730 (97.1)	1.00	1.00	23,334 (96.8)	1.00	1.00	738 (96.9)	1.00	1.00
<7	2,216 (2.1)	1,163 (2.6)	**1.28 (1.19-1.38)**	**1.48 (1.35-1.62) [d]**	690 (2.9)	**1.39 (1.28-1.52)**	**1.53 (1.40-1.68) [d]**	21 (2.8)	1.34 (0.87-2.07)	1.52 (0.97-2.36) [d]
Missing	635 (0.6)	105 (0.2)	n/a	n/a	75 (0.3)	n/a	n/a	3 (0.4)	n/a	n/a
Cryptorchidism (only males included)										
No	54,509 (99.3)	22,616 (99.0)	1.00	1.00	12,247 (99.1)	1.00	1.00	394 (99.4)	1.00	1.00
Yes	357 (0.7)	236 (1.0)	**1.59 (1.35-1.88)**	0.92 (0.77-1.11) [b]	107 (0.9)	**1.33 (1.07-1.66)**	0.87 (0.69-1.09) [b]	1 (0.3)	0.39 (0.05-2.77)	0.28 (0.04-1.98) [b]
Neural Tube Defects										

No	107,093 (99.9)	43,928 (99.8)	1.00	1.00	24,077 (99.9)	1.00	1.00	762 (100)	1.00	1.00
Yes	50 (0.1)	70 (0.2)	**3.41 (2.37-4.91)**	**1.64 (1.08-2.47)** [b]	22 (0.1)	**1.96 (1.19-3.23)**	1.21 (0.71-2.06) [b]	0 (0.0)	n/a	n/a
Amniotic Band Defects										
No	107,053 (99.9)	43,936 (99.9)	1.00	1.00	24,070 (99.9)	1.00	1.00	760 (99.7)	1.00	1.00
Yes	90 (0.1)	62 (0.1)	**1.68 (1.21-2.32)**	1.02 (0.71-1.47) [b]	29 (0.1)	1.43 (0.94-2.18)	0.98 (0.63-1.52) [b]	2 (0.3)	3.13 (0.77-12.73)	2.29 (0.56-9.37) [b]
Hypospadias (only males included)										
No	54,607 (99.5)	22,600 (98.9)	1.00	1.00	12,258 (99.2)	1.00	1.00	390 (98.7)	1.00	1.00
Yes	259 (0.3)	252 (1.1)	**2.35 (1.98-2.80)**	**1.27 (1.05-1.54)** [b]	96 (0.8)	**1.65 (1.31-2.09)**	1.07 (0.84-1.37) [b]	5 (1.3)	**2.70 (1.11-6.59)**	1.91 (0.78-4.68) [b]
Gastroschisis										
No	107,120 (99.9)	43,979 (99.9)	1.00	1.00	24,089 (99.9)	1.00	1.00	762(100)	1.00	1.00
Yes	23 (0.1)	19 (0.1)	**2.01 (1.10-3.70)**	1.10 (0.56-2.20) [b]	10 (0.1)	1.93 (0.92-4.06)	0.99 (0.45-2.21) [b]	0 (0.0)	n/a	n/a
At least one outcome*										
No	106,367 (99.3%)	43,363 (98.6%)	1.00	1.00	23,835 (98.9%)	1.00	1.00	754 (99.0%)	1.00	1.00
Yes	776 (0.7%)	635 (1.4%)	**2.01 (1.81-2.23)**	1.12 (0.99-1.26) [b]	264 (1.1%)	**1.52 (1.32-1.75)**	0.97 (0.84-1.13) [b]	8 (1.0%)	1.45 (0.72-2.93)	1.11 (0.55-2.23) [b]

n/a, not applicable; n, number of pregnancies

[a] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, maternal hypertensive disorders, maternal antepartum

haemorrhage

[b] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, gestation at delivery

[c] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking

[d] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, type of delivery

*Including cryptorchidism, neural tube defects, amniotic band defects, hypospadias, gastroschisis

Table 3. Sub-group regression analysis between control pregnancies and exposed to diclofenac.

Outcomes	No analgesic (n=20,544) n (%)	Diclofenac 2005-2015 (n=10,291) n (%)	Crude OR (CI 95%)	Adjusted OR (CI 95%)
Gestation at delivery (weeks)				
>=37	19,407 (94.5%)	9,640 (93.7%)	1.00	1.00
<37	1,137 (5.5%)	651 (6.3%)	**1.15 (1.04, 1.27)**	1.10 (0.99, 1.22) [a]
Pregnancy outcome				
Livebirth	20,393 (99.3%)	10,227 (99.4%)	1.00	1.00
Stillbirth	116 (0.5%)	39 (0.4%)	**0.67 (0.47, 0.96)**	**0.59 (0.41, 0.87) [a]**
Neonatal Death	35 (0.2%)	25 (0.2%)	1.42 (0.85, 2.38)	1.26 (0.73, 2.15) [a]
Weight of baby (grams)				
NBW	16,869 (82.1%)	8,116 (78.9%)	1.00	1.00
LBW	965 (4.7%)	572 (5.6%)	**1.23 (1.11, 1.37)**	**1.22 (1.07, 1.40) [b]**
HBW	2,707 (13.2%)	1,600 (15.5%)	**1.23 (1.15, 1.31)**	**1.21 (1.13, 1.29) [b]**
Missing	3 (0.0%)	3 (0.0%)		
Standardised Birthweight Score				
	-0.039 (0.959)	0.132 (1.036)	**0.171 (0.145, 0.197)**	**0.167 (0.141, 0.193) [c]**
Admitted to neonatal unit				
No	18,224 (88.7%)	8,747 (85.0%)	1.00	1.00
Yes	2,175 (10.6%)	1,492 (14.5%)	**1.43 (1.33, 1.53)**	**1.46 (1.35, 1.58) [b]**
Missing	145 (0.7%)	52 (0.5%)		
APGAR score at 1 min				
Normal	18,709 (91.1%)	9,350 (90.9%)	1.00	1.00
<7	1,658 (8.1%)	924 (9.0%)	**1.12 (1.03, 1.21)**	0.93 (0.83, 1.04) [d]
Missing	177 (0.9%)	17 (0.2%)		
APGAR score at 5 min				
Normal	20,065 (97.7%)	10,096 (98.1%)	1.00	1.00
<7	302 (1.5%)	177 (1.7%)	0.86 (0.71, 1.04)	0.94 (0.72, 1.23) [d]
Missing	177 (0.9%)	18 (0.2%)		
Cryptorchidism (only males included)				
No	10,284 (98.7%)	5,314 (98.7%)	1.00	1.00
Yes	133 (1.3%)	70 (1.3%)	1.02 (0.76, 1.36)	1.05 (0.78, 1.42) [b]
Neural Tube Defects				
No	20,527 (99.9%)	10,263 (99.7%)	1.00	1.00
Yes	17 (0.1%)	28 (0.3%)	**3.29 (1.80, 6.02)**	**3.62 (1.95, 6.74) [b]**
Amniotic Band Defects				
No	20,514 (99.9%)	10,277 (99.9%)	1.00	1.00
Yes	30 (0.1%)	14 (0.1%)	0.93 (0.49, 1.76)	0.81 (0.41, 1.58) [b]
Hypospadias (only males included)				
No	10,317 (99.0%)	5,308 (98.6%)	1.00	1.00
Yes	100 (1.0%)	76 (1.4%)	**1.48 (1.09, 1.99)**	**1.49 (1.09, 2.03) [b]**
Gastroschisis				
No	20,538 (99.9%)	10,284 (99.9%)	1.00	1.00
Yes	6 (0.1%)	7 (0.1%)	2.33 (0.78, 6.94)	2.93 (0.97, 8.88) [b]
At least one outcome*				
No	20,258 (98.6%)	10,097 (98.1%)	1.00	1.00
Yes	286 (1.4%)	194 (1.9%)	**1.36 (1.13, 1.64)**	**1.38 (1.15, 1.67) [b]**

n/a, not applicable; n, number of pregnancies

[a] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, maternal

hypertensive disorders, maternal antepartum haemorrhage

[b] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, gestation at

delivery

[c] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking

538 [d] Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, type of

539 delivery

540 *Including cryptorchidism, neural tube defects, amniotic band defects, hypospadias, gastroschisis

Figure 1. Flowchart of cohort selection and sub-group analyses. n=number of

pregnancies in each analysis,*98.3% of pregnancies using only diclofenac were

during 2005-2015, therefore analysis was performed only on data from that decade

to rule out any temporal effect

549 **Figure 2.** Prevalence of use during pregnancy for each analgesic sub-group over our

550 30-year study period. In 2005 there was a change in legislation making diclofenac

551 available without prescription

Figure S1. Directed acyclic graph (DAG) of exposure to outcome path

and relevant measured and unmeasured biasing factors in our analysis